ReviewOdontology2026
Clinical effectiveness of albumin-enriched platelet-rich fibrin (Alb-PRF) in periodontal and peri-implant regenerative surgery: a systematic review.
Review in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alb-PRF is a heat-induced autologous fibrin biomaterial generated by combining thermally denatured serum albumin with liquid platelet-rich fibrin. Although its clinical use in periodontal and peri-implant procedures has increased, the available evidence remains limited and methodologically heterogeneous. This systematic review aimed to synthesize the biological rationale, clinical effectiveness, and methodological quality of Alb-PRF in periodontal and peri-implant applications. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and the Cochrane Library from January 2013 to December 2025 in accordance with PRISMA 2020 guidelines. Grey literature sources, including Google Scholar and OpenGrey, were also screened. Randomized and controlled clinical trials as well as relevant in vivo animal studies evaluating Alb-PRF were included. Study selection and data extraction were independently performed by two reviewers using Rayyan, and methodological quality was assessed using the RoB-2, Newcastle-Ottawa Scale, or SYRCLE tools. Due to substantial heterogeneity in study design, clinical indications, and outcome measures, a narrative synthesis was performed. Seven studies were included (six clinical and one animal study), comprising 156 human participants and 24 animal samples, with follow-up periods ranging from 7 days to 6 months. Alb-PRF showed consistent benefits in early soft-tissue healing and postoperative comfort. However, evidence supporting its role in hard-tissue regeneration remains limited and inconclusive. Based on current evidence, Alb-PRF should be biologically interpreted as a soft-tissue phenotype-modulating adjunct that stabilizes the early healing microenvironment rather than as a primary hard-tissue regenerative material. Its clinical utility appears to be indication-specific and mainly related to early soft-tissue outcomes. Well-designed, standardized randomized controlled trials with longer follow-up periods are required to clarify its therapeutic role. PROSPERO registration number: CRD420251237466 (registered on 21 November 2025, version 1.0).
Indexed as
Identifiers
41984123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.